Table 1.

Quantification of changes in core fucosylation of glycopeptides in liver disease.

Protein name	Peptidea	Core fucosylation level in percent (mean ± SD)			p value (ANOVA)
		Control	Fibrosis	Cirrhosis
Ig gamma-2 chain C region	EEQF180NSTFR	91.4 ± 2.75	84.9 ± 13.47	87.5 ± 3.95	0.107
Immuno globulin J chain	E71NISDPTSPLR	16.8 ± 2.6	17.9 ± 4.07	20.3 ± 2.34	0.013
Ig alpha-2 chain C region	TPLTA205NITK	36.2 ± 17.03	30.2 ± 12.97	38 ± 14.7	0.340
Hemopexin	SWPAVG187NCSSALR	9.9 ± 2.41	12.8 ± 3.18	14 ± 5.24	0.016
Complement C3	TVLTPATNHmG85NVTFTIPANR	14.3 ± 10.39	10.4 ± 5.84	11.8 ± 6.6	0.430
Alpha-2-HS-glycoprotein	AALAAFNAQN176NGSNFQLEEISR	15.5 ± 4.57	17.7 ± 4.01	16.8 ± 5.71	0.456
Fibronectin	LDAPTNLQFV1007NETDSTVLVR	98.6 ± 0.64	98.6 ± 0.86	98.4 ± 0.67	0.671
Complement C1q subcomponent subunit A	NPPMGGNWIFDTVITNQEEPYQ146NHSGR	45.3 ± 14.86	49 ± 11.54	49.2 ± 10.63	0.624
Serotransferrin	QQQHLFGS630NVTDCSGNFCLFR	7.7 ± 1.85	10.6 ± 2.17	11.6 ± 4.69	0.004
Plasma protease C1 inhibitor	VLS253NNSDANLELINTWVAK	34 ± 5.46	41.7 ± 5.25	43.8 ± 11.84	0.005
Pigment epithelium-derived, factor	VTQ285NLTLIEESLTSEFIHDIDR	79.9 ± 10.68	76.9 ± 11.52	83.3 ± 6.13	0.224
Alpha-2-macroglobulin	GCVLLSYL55NETVTVSASLESVR	72.3 ± 11.72	66.3 ± 11.72	66.4 ± 10.88	0.271
Clusterin	ML354NTSSLLEQLNEQFNWVSR	5.5 ± 0.95	6.7 ± 1.57	8.6 ± 2.4	0.000
Alpha-1-antitrypsin	QLAHQS70NSTNIFFSPVSIATAFAMLSLGTK	27.9 ± 15.05	27.3 ± 11.24	29.7 ± 11.71	0.875
	ADTHDEILEGLNF107NLTEIPEAQIHEGFQELLR	6.9 ± 1.95	9.9 ± 2.36	11.4 ± 4.48	0.001
Lumican	AFE88NVTDLQWLILDHNLLENSK	91.8 ± 2.75	90.3 ± 10.43	94.4 ± 0.89	0.234
	LHINHN127NLTESVGPLPK	54.5 ± 3.9	58.1 ± 4.84	58.9 ± 4.06	0.016
Vitronectin	169NGSLFAFR	21.7 ± 7.96	14.6 ± 7.92	13.8 ± 7.82	0.017
	N86NATVHEQVGGPSLTSDLQAQSK	5.6 ± 3.15	12.2 ± 6.15	12.6 ± 6.2	0.001
Ceruloplasmin	E397NLTAPGSDSAVFFEQGTTR	9.6 ± 2.34	14.4 ± 2.94	14.9 ± 4.74	0.002
	EHEGAIYPD138NTTDFQR	26 ± 3.86	30.3 ± 5.14	32.4 ± 8.91	0.026
	ELHHLQEQ762NVSNAFLDK	2.1 ± 0.42	2.5 ± 0.38	3.2 ± 1.53	0.009

^aModified glycosylation site is shown in italic.